Firstline nivolumab plus ipilimumab shows durable OS after 4 years in patients with pleural mesothelioma
The phase 3 CheckMate 743 study shows prolonged OS for patients with unresectable malignant pleural mesothelioma treated with nivolumab plus ipilimumab vs. chemotherapy. Directly from ESMO 2022, Professor Gerard Zalcman presents the 4-year update of the study, showing that the double immunotherapy continued to provide long-term, durable OS beneﬁt for this group of patients vs. chemotherapy.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.